☰

Brent D. Page, Ph.D. - Publications

Affiliations: 
2013 Chemistry University of Toronto, Toronto, ON, Canada 
Area:
Biochemistry, Organic Chemistry, Oncology, Cell Biology, Medicine and Surgery
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Jaworski C, Iliev P, Wängler C, Wängler B, Page B, Schirrmacher R, Bailey JJ. Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update. Expert Opinion On Therapeutic Patents. 1-19. PMID 37735897 DOI: 10.1080/13543776.2023.2262136  0.303
2020 Busker S, Page B, Arnér ESJ. To inhibit TrxR1 is to inactivate STAT3-Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors. Redox Biology. 36: 101646. PMID 32863208 DOI: 10.1016/j.redox.2020.101646  0.509
2020 Busker S, Page B, Arnér ES. To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors Redox Biology. 36: 101646. DOI: 10.1016/J.Redox.2020.101646  0.584
2019 Heppler LN, Walker SR, Attarha S, Page BD, Frank DA. Abstract 387: Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate reductase Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-387  0.535
2016 Belton A, Xian L, Huso T, Koo M, Luo LZ, Turkson J, Page BD, Gunning PT, Liu G, Huso DL, Resar LM. STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway. Leukemia & Lymphoma. 1-4. PMID 26952843 DOI: 10.3109/10428194.2016.1153089  0.615
2016 Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BD, Kamocka MM, Haftchenary S, Su H, Ball DP, Rosa DA, Lai PS, Gomez-Biagi RF, Ali AM, Rana R, et al. Applying Small Molecule Signal Transducer and Activator of Trancription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Molecular Cancer Therapeutics. PMID 26873728 DOI: 10.1158/1535-7163.Mct-15-0003  0.7
2015 Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. PMID 26314961 DOI: 10.18632/Oncotarget.4742  0.648
2015 Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 29: 586-97. PMID 25134459 DOI: 10.1038/Leu.2014.245  0.66
2015 Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, et al. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation Oncotarget. 6: 27461-27477. DOI: 10.18632/oncotarget.4742  0.555
2014 Eiring AM, Kraft IL, Page BD, O'Hare T, Gunning PT, Deininger MW. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leukemia Supplements. 3: S5-6. PMID 27175272 DOI: 10.1038/leusup.2014.3  0.553
2014 Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, ... Page BD, et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Science Signaling. 7: ra38. PMID 24757178 DOI: 10.1126/Scisignal.2004839  0.698
2014 Heaton WL, Eiring AM, Vellore NA, Resetca D, Haftchenary S, Rosa D, Ali AM, Senina AV, Pomicter AD, Page BD, Kraft IL, Reynolds KR, Wilson DJ, Baron R, O'Hare T, et al. Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders Blood. 124: 4816-4816. DOI: 10.1182/Blood.V124.21.4816.4816  0.675
2013 Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-Awar R, Weiss S, et al. Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. Acs Medicinal Chemistry Letters. 4: 1102-7. PMID 24900612 DOI: 10.1021/ml4003138  0.8
2013 Page BD, Croucher DC, Li ZH, Haftchenary S, Jimenez-Zepeda VH, Atkinson J, Spagnuolo PA, Wong YL, Colaguori R, Lewis AM, Schimmer AD, Trudel S, Gunning PT. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. Journal of Medicinal Chemistry. 56: 7190-200. PMID 23968501 DOI: 10.1021/Jm3017255  0.729
2013 Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BD, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. Embo Molecular Medicine. 5: 572-90. PMID 23460527 DOI: 10.1002/Emmm.201201876  0.576
2013 Eiring AM, Kraft IL, Page BD, Zhang TY, Khorashad JS, Vellore NA, Reynolds KR, Pomicter AD, Senina AV, Zabriskie MS, Ahmad S, Mason CC, Moriggl R, Baron R, O'Hare T, et al. BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia Blood. 122: 854-854. DOI: 10.1182/Blood.V122.21.854.854  0.642
2013 Croucher DC, Li Z, Page BD, Wei EN, Gunning PT, Trudel S. A Novel Small Molecule STAT Inhibitor, BP-4-018, Demonstrates Significant Anti-Tumour Activity and Synergism With Bortezomib In Pre-Clinical In Vivo Models Of Multiple Myeloma Blood. 122: 4441-4441. DOI: 10.1182/Blood.V122.21.4441.4441  0.748
2013 Croucher DC, Li ZH, Page BD, Wei E, Gunning PT, Trudel S. Abstract A260: BP-4-018, a novel inhibitor of STATs demonstrates anti-myeloma activity in preclinical models: Therapeutic implications of targeting aberrant STAT3 signaling in multiple myeloma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A260  0.776
2012 Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT, Turkson J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America. 109: 9623-8. PMID 22623533 DOI: 10.1073/Pnas.1121606109  0.708
2012 Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, Yue P, Turkson J, Minden MD, Gunning PT. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. Journal of Medicinal Chemistry. 55: 1047-55. PMID 22148584 DOI: 10.1021/Jm200720N  0.746
2012 Mitra RN, Doshi M, Zhang X, Tyus JC, Bengtsson N, Fletcher S, Page BD, Turkson J, Gesquiere AJ, Gunning PT, Walter GA, Santra S. An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials. 33: 1500-8. PMID 22078810 DOI: 10.1016/J.Biomaterials.2011.10.068  0.526
2012 Jimenez-Zepeda VH, Page BD, Hua LZ, Wei E, Bergsagel L, Gunning PT, Trudel S. BP-2-047, a Novel Small-Molecule Inhibitor of Stat3 Is Active in Myeloma Pre-Clinical Models: Rationale for Treatment of Stat3-Dependent Multiple Myeloma Blood. 120: 576-576. DOI: 10.1182/Blood.V120.21.576.576  0.769
2012 Eiring AM, Kraft IL, Page BD, Anderson DJ, Gu Z, Khorashad JS, Pomicter AD, Reynolds KR, Zabriskie MS, Moriggl R, Gunning PT, O'Hare T, Deininger MW. STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML) Blood. 120: 31-31. DOI: 10.1182/Blood.V120.21.31.31  0.694
2012 Kraft IL, Eiring AM, Page BD, Mason CC, Gu Z, Khorashad JS, Anderson DJ, Pomicter AD, Reynolds KR, Estrada J, Zabriskie MS, Gunning PT, O'Hare T, Deininger MW. Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia. Blood. 120: 2445-2445. DOI: 10.1182/Blood.V120.21.2445.2445  0.712
2012 Yue P, Zhang X, Page BD, Zhao W, Paladino D, Gunning PT, Turkson J. Abstract LB-354: A novel orally-bioavailable small-molecule inhibitor of Stat3 regresses human breast and lung cancer xenografts Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-354  0.748
2011 Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorganic & Medicinal Chemistry Letters. 21: 5605-9. PMID 21788134 DOI: 10.1016/J.Bmcl.2011.06.056  0.762
2011 Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. Chemmedchem. 6: 1459-70. PMID 21618433 DOI: 10.1002/Cmdc.201100194  0.71
2011 Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opinion On Therapeutic Patents. 21: 65-83. PMID 21114420 DOI: 10.1517/13543776.2011.539205  0.72
2011 Croucher DC, Jimenez-Zepeda VH, Li ZH, Wei E, Page BD, Turkson J, Gunning PT, Trudel S. The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia Blood. 118: 5101-5101. DOI: 10.1182/Blood.V118.21.5101.5101  0.769
2011 Croucher DC, Jimenez-Zepeda VH, Page BD, Li ZH, Wei E, Turkson J, Gunning PT, Trudel S. Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A201  0.771
2010 Jimenez-Zepeda VH, Li ZH, Page BD, Zeng S, Wei E, Leung-Hagesteijn C, Turkson J, Gunning PT, Trudel S. Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity Blood. 116: 138-138. DOI: 10.1182/Blood.V116.21.138.138  0.754
2009 Fletcher S, Drewry JA, Shahani VM, Page BD, Gunning PT. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 87: 825-33. PMID 19935868 DOI: 10.1139/o09-044  0.726
2009 Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem : a European Journal of Chemical Biology. 10: 1959-64. PMID 19644994 DOI: 10.1002/Cbic.200900172  0.809
Show low-probability matches.